Summary
Sorrento Therapeutics Inc (STI), formerly QuikByte Software, Inc., which develops novel treatments for cancer, inflammation and autoimmune diseases. It discovers small molecules, antibody drug conjugates, and antibodies for the treatment of cancer and its associated pain. Its pipeline products include mAbs, CAR-T, CAR.TNK and resiniferatoxin. STI’s product Cynviloq is a novel nanoparticle formulation of paclitaxel, is used for the treatment of metastatic breast cancer, pancreatic cancer and non-small cell lung cancer. The company works in collaboration with biopharmaceutical companies and academic institutions to develop the novel immunotherapies. It also operates through its subsidiaries. STI is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 11
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 15
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 16
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 20
Venture Financing 21
Scilex Pharma Raises USD0.5 Million in Financing 21
Scilex Pharma Raises US$5 Million In Venture Financing 22
Partnerships 23
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 23
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 24
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 25
Sorrento Therapeutics to Form Joint Venture with Yuhan 26
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 27
Sorrento Therapeutics and NantBioscience Form Joint Venture 28
Advaxis Enters into Research Agreement with Sorrento Therapeutics 29
Sorrento Therapeutics Enters into Co-Development Agreement with Conkwest 30
NantWorks to Form Joint Venture with Sorrento Therapeutics 31
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 32
Sorrento Therapeutics Enters Into Co-Development Agreement With The Scripps Research Institute 33
Licensing Agreements 34
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 34
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 36
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 37
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 38
NantWorks to Enter into Licensing Agreement with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 40
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 42
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 44
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 45
Equity Offering 46
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 46
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 48
Sorrento Therapeutics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 50
Scilex Pharma Announces Private Placement Of Shares And Warrants For US$5 Million 52
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 53
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 55
Sorrento Therapeutics Completes Private Placement Of Shares For US$2 Million 56
Acquisition 57
TNK Therapeutics to Acquire Virttu Biologics 57
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 58
Scintilla Pharma to Acquire Semnur Pharma 59
TNK Therapeutics Acquires Two Biotechnology Companies 60
NantPharma Acquires IgDraSol from Sorrento Therapeutics 61
Itochu Chemical Frontier Invests in Scilex Pharma 62
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 63
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 64
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 65
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 66
Sorrento Therapeutics Inc - Key Competitors 68
Key Employees 69
Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71
List of Tables
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Sorrento Therapeutics Inc, Deals By Therapy Area, 2010 to YTD 2016 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 11
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 15
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 16
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 20
Scilex Pharma Raises USD0.5 Million in Financing 21
Scilex Pharma Raises US$5 Million In Venture Financing 22
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 23
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 24
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 25
Sorrento Therapeutics to Form Joint Venture with Yuhan 26
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 27
Sorrento Therapeutics and NantBioscience Form Joint Venture 28
Advaxis Enters into Research Agreement with Sorrento Therapeutics 29
Sorrento Therapeutics Enters into Co-Development Agreement with Conkwest 30
NantWorks to Form Joint Venture with Sorrento Therapeutics 31
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 32
Sorrento Therapeutics Enters Into Co-Development Agreement With The Scripps Research Institute 33
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 34
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 36
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 37
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 38
NantWorks to Enter into Licensing Agreement with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 40
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 42
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 44
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 45
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 46
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 48
Sorrento Therapeutics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 50
Scilex Pharma Announces Private Placement Of Shares And Warrants For US$5 Million 52
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 53
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 55
Sorrento Therapeutics Completes Private Placement Of Shares For US$2 Million 56
TNK Therapeutics to Acquire Virttu Biologics 57
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 58
Scintilla Pharma to Acquire Semnur Pharma 59
TNK Therapeutics Acquires Two Biotechnology Companies 60
NantPharma Acquires IgDraSol from Sorrento Therapeutics 61
Itochu Chemical Frontier Invests in Scilex Pharma 62
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 63
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 64
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 65
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 66
Sorrento Therapeutics Inc, Key Competitors 68
Sorrento Therapeutics Inc, Key Employees 69
Sorrento Therapeutics Inc, Subsidiaries 70
List of Figures
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Sorrento Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 11
